First National Trust Co Trims Holdings in Boston Scientific Co. (NYSE:BSX)

First National Trust Co decreased its holdings in Boston Scientific Co. (NYSE:BSX) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 233,299 shares of the medical equipment provider’s stock after selling 29,779 shares during the quarter. First National Trust Co’s holdings in Boston Scientific were worth $13,487,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. Commonwealth Equity Services LLC raised its position in Boston Scientific by 7.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 201,364 shares of the medical equipment provider’s stock valued at $10,632,000 after purchasing an additional 13,121 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in Boston Scientific by 25.9% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 42,606 shares of the medical equipment provider’s stock worth $2,250,000 after buying an additional 8,766 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its position in Boston Scientific by 2.8% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 465,701 shares of the medical equipment provider’s stock worth $24,589,000 after buying an additional 12,757 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in Boston Scientific by 30.0% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 492,827 shares of the medical equipment provider’s stock worth $26,021,000 after buying an additional 113,832 shares during the last quarter. Finally, Stratos Wealth Advisors LLC purchased a new position in Boston Scientific during the 3rd quarter worth $252,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the transaction, the chief financial officer now directly owns 271,542 shares in the company, valued at approximately $17,883,756.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares in the company, valued at approximately $3,779,820.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Daniel J. Brennan sold 13,662 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the transaction, the chief financial officer now owns 271,542 shares in the company, valued at $17,883,756.12. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock worth $5,395,560 in the last three months. Company insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 1.1 %

Shares of Boston Scientific stock traded up $0.82 during mid-day trading on Friday, hitting $72.85. 7,452,084 shares of the stock were exchanged, compared to its average volume of 7,241,391. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39. The stock has a market capitalization of $106.88 billion, a price-to-earnings ratio of 61.22, a price-to-earnings-growth ratio of 2.51 and a beta of 0.77. The company has a 50-day simple moving average of $68.42 and a 200 day simple moving average of $61.27. The company has a current ratio of 1.66, a quick ratio of 0.82 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.04. The company had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.59 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. During the same period last year, the company earned $0.45 EPS. Research analysts forecast that Boston Scientific Co. will post 2.32 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on BSX shares. Raymond James upped their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Argus upped their price target on shares of Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. TD Cowen upped their price target on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research note on Thursday, March 7th. Mizuho upped their price target on shares of Boston Scientific from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Finally, Wells Fargo & Company upped their price target on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.09.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.